Security
Collegium Pharmaceutical, Inc. Common Stock · COLL
COLLNASDAQCommon stockCurrentCIK 1267565Updated Oct 4, 2026
Name history
COLLEGIUM PHARMACEUTICAL INC · through Mar 3, 2015
COLL price & chart
Loading TradingView…
NASDAQ:COLL on TradingView ↗About the company
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
In the news
Collegium Announces $50 Million Accelerated Share Repurchase Program ↗
Recent filings
SCHEDULE 13G - filed by INTEGRATED CORE STRATEGIES (US) LLC regarding COLLEGIUM PHARMACEUTICAL, INC
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01
SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding COLLEGIUM PHARMACEUTICAL, INC
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,656,834,000Source | 1,663,591,000Source | 1,143,308,000Source | 1,174,131,000Source |
| Property, Plant and Equipment, NetUSD | 12,013,000Source | 14,329,000Source | 15,983,000Source | 19,521,000Source |
| GoodwillUSD | 145,925,000Source | 162,333,000Source | 133,857,000Source | 133,695,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 669,510,000Source | 891,402,000Source | 421,708,000Source | 567,468,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 231,252,000Source | 70,565,000Source | 238,947,000Source | 173,688,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 211,328,000Source | 228,540,000Source | 179,525,000Source | 183,119,000Source |
| Inventory, NetUSD | 40,912,000Source | 35,560,000Source | 32,332,000Source | 46,501,000Source |
| Assets, CurrentUSD | 691,411,000Source | 482,257,000Source | 537,600,000Source | 419,989,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 32,642,000Source | 30,394,000Source | 15,195,000Source | 16,681,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,187,000Source | 5,822,000Source | 6,029,000Source | 6,861,000Source |
| Other Assets, NoncurrentUSD | 20,193,000Source | 8,368,000Source | 825,000Source | 100,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,355,159,000Source | 1,434,749,000Source | 947,877,000Source | 979,289,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 41,000Source | 40,000Source | 38,000Source | 37,000Source |
| Additional Paid in CapitalUSD | 624,954,000Source | 590,251,000Source | 565,949,000Source | 538,073,000Source |
| Retained Earnings (Accumulated Deficit)USD | -101,129,000Source | -163,999,000Source | -233,189,000Source | -281,344,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 319,000Source | 55,000Source | 14,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 301,675,000Source | 228,842,000Source | 195,431,000Source | 194,842,000Source |
| Liabilities and EquityUSD | 1,656,834,000Source | 1,663,591,000Source | 1,143,308,000Source | 1,174,131,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 440,028,000Source | 509,510,000Source | 457,915,000Source | 433,726,000Source |
| Operating Lease, Liability, CurrentUSD | 1,407,000Source | 1,271,000Source | 988,000Source | 1,112,000Source |
| Accounts Payable, CurrentUSD | 10,659,000Source | 3,934,000Source | 8,692,000Source | 3,494,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,132,000Source | 5,539,000Source | 6,124,000Source | 7,112,000Source |
| Deferred Income Tax Liabilities, NetUSD | 29,141,000Source | 54,191,000Source | 71,165,000Source | 94,540,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 62,464,000Source | 72,124,000Source | 37,571,000Source | 36,129,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 62,870,000Source | 69,190,000Source | 48,155,000Source | -25,002,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 41,906,000Source | 32,400,000Source | 27,136,000Source | 22,874,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -17,204,000Source | 4,414,000Source | -3,594,000Source | 21,780,000Source |
| Increase (Decrease) in InventoriesUSD | 5,353,000Source | -13,927,000Source | -14,169,000Source | -48,274,000Source |
| Increase (Decrease) in Accounts PayableUSD | 6,718,000Source | -11,278,000Source | 5,061,000Source | -707,000Source |
| Deferred Income Tax Expense (Benefit)USD | -25,657,000Source | -26,814,000Source | -2,153,000Source | -8,391,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 329,323,000Source | 204,980,000Source | 274,749,000Source | 124,230,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | — | — | 572,069,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -63,532,000Source | -287,759,000Source | -70,812,000Source | -573,691,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,740,000Source | 1,652,000Source | 461,000Source | 1,622,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 12,846,000Source | 19,170,000Source | 8,361,000Source | 4,044,000Source |
| Payments for Repurchase of Common StockUSD | 25,104,000Source | 60,025,000Source | 75,000,000Source | 14,063,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -110,245,000Source | -60,603,000Source | -140,178,000Source | 436,723,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 252,158,000Source | 96,612,000Source | 239,994,000Source | 176,235,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 68,760,000Source | 62,434,000Source | 73,256,000Source | 52,528,000Source |
| Income Taxes Paid, NetUSD | 60,041,000Source | 52,090,000Source | 24,205,000Source | 10,400,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 32,400,000Source | 27,136,000Source | 22,874,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 5,341,000Source | 6,016,000Source | 8,635,000Source | 8,285,000Source |
| Amortization of Intangible AssetsUSD | 221,892,000Source | — | — | — |
| DepreciationUSD | 4,182,000Source | 3,856,000Source | 3,496,000Source | 2,684,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -15,994,000Source | -11,329,000Source | -23,504,000Source | — |
| GoodwillUSD | 145,925,000Source | 162,333,000Source | 133,857,000Source | 133,695,000Source |
| Income Tax Expense (Benefit)USD | 29,749,000Source | 29,378,000Source | 27,578,000Source | -3,845,000Source |
| InterestExpenseNonoperatingUSD | 82,312,000Source | 73,974,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 62,870,000Source | 69,190,000Source | 48,155,000Source | -25,002,000Source |
| Operating ExpensesUSD | 283,621,000Source | 207,449,000Source | 159,208,000Source | 176,169,000Source |
| Proceeds from Stock Options ExercisedUSD | 4,280,000Source | 10,246,000Source | 8,641,000Source | 11,811,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 780,567,000Source | 631,449,000Source | 566,767,000Source | 463,933,000Source |
| Cost of RevenueUSD | 317,310,000Source | 254,105,000Source | 240,598,000Source | 254,445,000Source |
| Selling, General and Administrative ExpenseUSD | 284,803,000Source | 210,363,000Source | 159,208,000Source | 172,186,000Source |
| Operating Income (Loss)USD | 179,636,000Source | 169,895,000Source | 166,961,000Source | 33,319,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 92,619,000Source | 98,568,000Source | 75,733,000Source | -28,847,000Source |
| Income Tax Expense (Benefit)USD | 29,749,000Source | 29,378,000Source | 27,578,000Source | -3,845,000Source |
| Net Income (Loss) Attributable to ParentUSD | 62,870,000Source | 69,190,000Source | 48,155,000Source | -25,002,000Source |
| Earnings Per Share, BasicUSD per share | 1.98Source | 2.14Source | 1.43Source | -0.74Source |
| Earnings Per Share, DilutedUSD per share | 1.73Source | 1.86Source | 1.29Source | -0.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 31,706,429Source | 32,273,850Source | 33,741,213Source | 33,829,495Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 39,701,693Source | 40,424,180Source | 41,788,125Source | 33,829,495Source |
| Interest Expense (non-operating)USD | 82,312,000Source | 73,974,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 221,892,000Source | — | — | — |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | 95,418,000Source | 88,801,000Source | 94,838,000Source | 118,190,000Source |
| Gross ProfitUSD | 463,257,000Source | 377,344,000Source | 326,169,000Source | 209,488,000Source |
| Interest ExpenseUSD | — | — | 83,339,000Source | 63,213,000Source |
| Investment Income, NetUSD | 11,289,000Source | 13,976,000Source | 15,615,000Source | 1,047,000Source |
| Marketing and Advertising ExpenseUSD | 27,779,000Source | — | — | — |
| Operating ExpensesUSD | 283,621,000Source | 207,449,000Source | 159,208,000Source | 176,169,000Source |
| Research and Development ExpenseUSD | — | 0Source | 0Source | 3,983,000Source |
Filing attachments
tm2618928d1_ex99-1.htm · 8-K/A · 2026-06-30
Exhibit 99.1 Consolidated Financial Statements and Report of Independent Certified Public Accountants Corium Therapeutics Holdings, LLC December 31, 2025 and 2024 Contents Page Report of Independent Certified 3 Public Accountants Report of Independent Auditors 6 Consolidated Financial Statements Consolidated balance sheets …
Read attachment ↗tm2618928d1_ex99-2.htm · 8-K/A · 2026-06-30
Exhibit 99.2 Condensed Consolidated Financial Statements Corium Therapeutics Holdings, LLC For the quarterly period ended March 31, 2026 Contents Page Condensed Consolidated Financial Statements Unaudited condensed consolidated 3 balance sheets Unaudited condensed consolidated 4 statements of operations a…
Read attachment ↗tm2614189d1_ex99-1.htm · 8-K · 2026-05-12
EX-99.1 3 tm2614189d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium Completes Acquisition of AZSTARYS ® from Corium Therapeutics - Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio - - Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 - - Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition - - 2026 Total Product Rev…
Read attachment ↗tm269336d1_ex99-1.htm · 8-K · 2026-03-19
EX-99.1 3 tm269336d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio - - Enables Greater Impact Across ADHD Patient Communities - - AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue - - Expected Patent Protectio…
Read attachment ↗tm269336d1_ex99-2.htm · 8-K · 2026-03-19
EX-99.2 4 tm269336d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Collegium to Acquire AZSTARYS ® from Corium Therapeutics March 19, 2026 | Nasdaq: COLL Healthier people. Stronger communities. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expe…
Read attachment ↗tm262493d1_ex99-1.htm · 8-K · 2026-01-08
EX-99.1 2 tm262493d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Collegium Provides 2026 Financial Guidance and Business Update - Product Revenues, Net Expected in the Range of $805 Million to $825 Million - - Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million - - Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million - STOUGHTON, Mass., January 8, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guid…
Read attachment ↗